Cellular processing of platinum anticancer drugs

By Dong Wang, S. Lippard. Nature reviews. Drug discovery, 2005

3,529 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/3184ddcb9fc6789d72c82b35ba88f6be8ff94347

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. Shaloam Dasari
2. P. Tchounwou

In Molecular Biology

1. M. Dolan
2. Oliver Kepp
3. Zheng Dong
4. Shaloam Dasari
5. A. Tesnière
6. Navjotsingh Pabla
7. L. Zitvogel
8. P. Tchounwou

In Oncology

1. L. Zitvogel
2. M. Dolan
3. Xueyun Gao
4. Oliver Kepp
5. Zheng Dong
6. Chao Xu
7. Chunyu Zhang
8. Shaloam Dasari

Citations in the corpus

• Immunogenic death of colon cancer cells treated with oxaliplatin (2010, background): “Discussion Oxaliplatin and CDDP are chemically related agents that induce apoptosis through DNA damage as well as cytoplasmic effects (”
• Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer (2017, background): “This absence of cross-resistance with cisplatin is due to the different mismatch-repair proteins that recognize each kind of adduct, and also explains their different side effects [279].”
• Platinum-based drugs for cancer therapy and anti-tumor strategies (2022, background): “This discovery opened up a new possibility for cancer chemotherapy [6, 7].”
• Mechanisms of Cisplatin Nephrotoxicity (2010, background): “Cisplatin binds to DNA leading to the formation of inter- and intrastrand cross-links, thereby arresting DNA synthesis and replication in rapidly proliferating cells [79].”
• Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. (2008, background): “In addition, the activation of DNA repair mechanisms has been implicated in cisplatin resistance in malignant cells.(2,3,5) Research on DNA DNA damage by cisplatin”
• Molecular mechanisms of resistance and toxicity associated with platinating agents. (2007, background): “diamminocyclohexane) platinum (II) (oxaliplatin) is an analog which does not share the same mechanism as cisplatin, and likewise does not share in cross-resistance (reviewed in [3]).”
• Cisplatin in cancer therapy: molecular mechanisms of action (2014, positive): “…M anuscript A uthor M anuscript A uthor M anuscript There is increasing awareness now that one important reason for cisplatin's performance is associated to the high mobility group (HMG) proteins that bind to DNA and protect the drug–DNA adducts against excision repair (Wang and Lippard, 2005).”